BACKGROUND: The introduction of drug-eluting stents (DES) has @entity146 compared with bare metal stents, but in-stent @entity715 remains a safety concern, necessitating prolonged dual anti-platelet therapy. The drug @entity4446 ( @entity7275 ) has been shown to have beneficial effects in a cell-specific fashion on smooth muscle cells (SMC), endothelial cells and macrophages. We generated and analyzed a novel bioresorbable polymer coated DES, releasing @entity7275 into the vessel wall, to reduce @entity256 by inhibiting SMC proliferation and decreasing @entity32 , without negatively affecting endothelialization of the stent surface. METHODS: Stents spray-coated with a bioresorbable polymer containing 0, 30 or 300  g @entity7275 were implanted in the iliac arteries of 17 male New Zealand White @entity95 . Animals were euthanized for stent harvest 1 week after implantation for evaluation of cellular stent coverage and after 4 weeks for morphometric analyses of the lesions. RESULTS: Four weeks after implantation, the high dose of @entity7275 attenuated @entity256 with 16% compared to controls. Reduced @entity8233 formation could at least partly be explained by an almost 2-fold induction of the cell cycle inhibiting kinase p27Kip1. Additionally, @entity32 score, the quantification of RAM11-positive cells in the vessel wall, was significantly reduced in the high dose group with 23% compared to the control group. Evaluation with scanning electron microscopy showed @entity7275 did not inhibit strut coverage 1 week after implantation. CONCLUSION: We demonstrate that novel stents coated with a bioresorbable polymer coating eluting @entity7275 inhibit @entity256 and @entity32 , while stimulating endothelial coverage. The @entity7275 -eluting stents demonstrate that @entity256 without leaving uncovered metal is feasible, bringing stents without risk of late @entity715 one step closer to the @entity1 .

Stents Eluting @entity4446 Reduce Neointima Formation and XXXX while Enhancing Strut Coverage in @entity95 .

@entity1 :: ('9606', 'Species') :: ['patient'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'attenuate inflammation'] @entity146 :: ('MESH:D001523', 'Disease') :: ['dramatically reduced restenosis rates'] @entity7275 :: ('CHEBI:50667', 'Chemical') :: ['6-MP'] @entity95 :: ('9986', 'Species') :: ['rabbits'] @entity256 :: ('MESH:D023903', 'Disease') :: ['inhibition of restenosis', 'restenosis'] @entity4446 :: ('MESH:D015122', 'Chemical') :: ['6-Mercaptopurine'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis'] @entity8233 :: ('MESH:D058426', 'Disease') :: ['neointima']
@entity32 :: (MESH:D007249,Disease) :: ['Inflammation']
